Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

91

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

91 results for “Nitazoxanide”

Learn how ShareScore rates datasets ↗
dryad36/100

Macrophage targeting of nitazoxanide-loaded transethosomal gel in cutaneous leishmaniasis

<p>Topical delivery is preferable over systemic delivery for cutaneous leishmaniasis (CL), because of its easy administration, reduced systemic adverse effects, and low cost. Nitazoxanide (NTZ) has broad-spectrum activity against various parasites and has the potential to avoid drug resistance developed by enzymatic mutations. NTZ oral formulation is being associated with severe dyspepsia and stomach pain. Herein, NTZ-transethosomes (NTZ-TES) were prepared and loaded into chitosan gel (NTZ-TEG) for topical delivery. NTZ-TES were prepared by thin-film-hydration method and optimized statistically via Box-Behnken method. The optimized formulation indicated excellent particle size (176 nm), PDI (0.093), zeta potential (-26.4 mV) and entrapment efficiency (EE, 86%). The TEM analysis showed spherical sized particles and FTIR analysis indicated no interaction among the excipients. Similarly, NTZ-TEG showed optimal pH, desirable viscosity and good spreadability. NTZ-TES and NTZ-TEG showed prolonged release behavior and higher skin penetration and deposition in epidermal/dermal layer of skin in comparison with the NTZ-dispersion. Moreover, NTZ-TES showed higher percentage inhibition, lower IC50 against promastigotes and higher macrophage uptake. Additionally, skin irritation and histopathology studies indicated the safe and non-irritant behavior of the NTZ-TEG. The obtained findings suggested the enhanced skin permeation and improved anti-leishmanial effect of NTZ when administered as NTZ-TEG.</p>

opencc-zeroOct 2022View details →
dryad36/100

The successful treatment of Enterocytozoon bieneusi Microsporidiosis with nitazoxanide in a patient with B-ALL: A case report

<div> <strong>Introduction</strong>: <em>Enterocytozoon</em> <em>bieneusi</em> (<em>E</em>. <em>bieneusi</em>) Microsporidia can cause opportunistic infections in immunocompromised patients and is also an emerging disease in these individuals. Its clinical manifestations are chronic diarrhea and severe wasting syndrome, these can be extremely debilitating and carry a significant risk of death for immunocompromised patients. Often, microsporidia cannot be confirmed immediately by routine examination and culture. Effective and available treatment options are limited for infections caused by <em>E</em>. <em>bieneusi</em> in humans. Such cases are very rare in the Chinese Mainland.</div> <div> </div> <div> <strong>Case Presentation</strong>: A 47-year-old male had recurrent, profuse watery diarrhea and abdominal discomfort for more than 7 months, with a fever for 5 days. Two years earlier, he received treatment with a modified BFM-90 protocol for acute B cell lymphoblastic leukemia and is currently in the final stages of maintenance therapy with oral methotrexate and mercaptopurine. The leukemia was assessed as still in remission two months ago. PET/CT showed massive peritoneal fluid accumulation and a high uptake area in the diffused peritoneum (SUVmax 12.57), suggesting tumor invasion or microbial infections. However, broad-spectrum antibacterial therapies were ineffective. Metagenomic sequencing of plasma and peritoneal fluid showed no suggestion of the existence of a tumor but instead showed a high sequence number of DNA and RNA of the Microsporidia. His albendazole treatment failed and subsequent treatment with nitazoxanide successfully resolved the infection.</div> <div> </div> <div> <strong>Conclusion</strong>: This case shows that we should consider the possibility of atypical pathogen infection in patients with hematologic malignancy who repeatedly develop unexplained diarrhea with wasting. mNGS can help rule out malignant neoplasms and diagnose infections. Our results suggest that nitazoxanide effectively treats <em>E</em>. <em>bieneusi</em> microsporidia infections. </div>

opencc-zeroDec 2022View details →
ClinicalTrials.gov36/100

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

ClinicalTrials.gov study NCT00991289. IPD Sharing: Not stated. Countries: 2. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Effects of Early Use of Nitazoxanide in Patients With COVID-19

ClinicalTrials.gov study NCT04552483. IPD Sharing: YES. Countries: 1. Publications: 4.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Nitazoxanide Versus Placebo for the Treatment of Hospitalized Subjects With Severe Acute Respiratory Illness

ClinicalTrials.gov study NCT02057757. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures

ClinicalTrials.gov study NCT01185028. IPD Sharing: Not stated. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19

ClinicalTrials.gov study NCT04486313. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)

ClinicalTrials.gov study NCT01276756. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Nitazoxanide Therapy for Patients With COVID-19 Pneumonia

ClinicalTrials.gov study NCT04561219. IPD Sharing: YES. Countries: 1. Publications: 7.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

ClinicalTrials.gov study NCT01227421. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

NNITS-Nitazoxanide for Norovirus in Transplant Patients Study

ClinicalTrials.gov study NCT03395405. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
dryad36/100

The successful treatment of Enterocytozoon bieneusi Microsporidiosis with nitazoxanide in a patient with B-ALL: A case report

Open the record for dataset details and reuse information.

publicDec 2022View details →
dryad36/100

Macrophage targeting of nitazoxanide-loaded transethosomal gel in cutaneous leishmaniasis

Open the record for dataset details and reuse information.

publicOct 2022View details →
ClinicalTrials.gov32/100

Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19

ClinicalTrials.gov study NCT04341493. IPD Sharing: YES. Countries: 1. Publications: 4.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov32/100

Interest of Nitazoxanide Treatment of Enterocytozoon Bieneusi Intestinal Microsporidiosis

ClinicalTrials.gov study NCT05417815. IPD Sharing: NO. Countries: 2. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management

ClinicalTrials.gov study NCT05184491. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Efficacy of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in HCV Genotype 4 and HIV Coinfection

ClinicalTrials.gov study NCT01529073. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19

ClinicalTrials.gov study NCT04348409. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus

ClinicalTrials.gov study NCT06010992. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Nitazoxanide for the Treatment of Prolonged Diarrhea in Children

ClinicalTrials.gov study NCT01326338. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record